254746-40-2

Upstream product

• 7697-28-1 4-bromo-3-methylbenzoic acid 
• 858124-35-3 4-bromo-3-formyl-benzoic acid methyl ester 
• 877624-37-8 methyl 4-bromo-3-(dibromomethyl)benzoate 
• 148547-19-7 4-Bromo-3-methylbenzoic acid methyl ester 
• 142031-67-2 methyl 4-bromo-3-(bromomethyl)benzoate 
• 254746-41-3 methyl 3-(acetyloxy)methyl-4-bromobenzoate 

Downstream Products

• 913002-22-9 N₃'-cyclopropyl-N₄-[3-(dibutylamino)propyl]-5'-fluoro-6'-methyl-N₂-1,3-thiazol-2-yl-2,3',4-biphenyltricarboxamide 
• 913002-23-0 N₃'-cyclopropyl-N₄-[3-(dimethylamino)-2,2-dimethylpropyl]-5'-fluoro-6'-methyl-N₂-1,3-thiazol-2-yl-2,3',4-biphenyltricarboxamide 
• 913002-18-3 N₃'-cyclopropyl-5'-fluoro-6'-methyl-N₄-[(1R)-1-phenylethyl]-N₂-1,3-thiazol-2-yl-2,3',4-biphenyltricarboxamide 
• 913002-79-6 methyl 5'-[(cyclopropylamino)carbonyl]-3'-fluoro-2'-methyl-2-[(1,3-thiazol-2-ylamino)carbonyl]-4-biphenylcarboxylate 

Relevant academic research and scientific papers

Imaging and Profiling of Proteins under Oxidative Conditions in Cells and Tissues by Hydrogen-Peroxide-Responsive Labeling

Reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) can inflict damage to biomolecules under oxidative stress and also act as signaling molecules at physiological levels. Here we developed a unique chemical tool to elucidate the biological role

SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

BTK INHIBITORS

Provided are Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising these compounds and their use in therapy. In particular, provided is the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.

TRICYCLIC PYRI DO-CARBOXAM I D E DERIVATIVES AS ROCK INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates

NOVEL COMPOUNDS

The present invention is directed to novel compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutica

Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists

Novel biphenyl sulfonamide compounds which are combined angiotensin and endothelin receptor antagonists are claimed along with methods of using such compounds in the treatment of conditions such as hypertension and other diseases, as well as pharmaceutica